Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
147.8 USD | +2.56% | +12.19% | -17.92% |
Apr. 23 | Sector Update: Health Care Stocks Rise in Afternoon Trading | MT |
Apr. 23 | BeiGene Says Tislelizumab Gets European Commission's Approval to Treat Non-Small Cell Lung Cancer; Shares Rise | MT |
Business Summary
Number of employees: 10,600
Sales per Business
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Pharmaceutical Products
100.0
%
| 1,416 | 100.0 % | 2,459 | 100.0 % | +73.65% |
Sales per region
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
United States
45.9
%
| 503 | 35.5 % | 1,128 | 45.9 % | +124.46% |
China
44.8
%
| 840 | 59.3 % | 1,102 | 44.8 % | +31.18% |
Europe
8.2
%
| - | - | 202 | 8.2 % | - |
Rest of World
1.1
%
| 73 | 5.2 % | 27 | 1.1 % | -63.70% |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 0 | 1,244,457,968 | 1,222,239,074 ( 98.21 %) | 0 | 98.21 % |
Holdings
Name | Equities | % | Valuation |
---|---|---|---|
LEAP THERAPEUTICS, INC. 2.87% | 734,844 | 2.87% | 1,954,685 $ |
Company contact information
Sector
Sales per region
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-17.92% | 15.06B | |
-0.75% | 104B | |
+3.99% | 97.42B | |
-0.03% | 22.2B | |
-16.52% | 21.23B | |
-10.39% | 18.33B | |
-42.33% | 16.35B | |
+5.78% | 13.98B | |
+28.41% | 11.66B | |
-25.15% | 8.22B |
- Stock Market
- Equities
- BGNE Stock
- Company BeiGene, Ltd.